Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Invex Therapeutics Ltd. ( (AU:IXC) ) has provided an announcement.
Invex Therapeutics Ltd announced the receipt of a £114k R&D tax rebate from the UK government, reflecting eligible research and development expenditures during the 2024 financial year. This financial gain supports Invex’s focus on innovating treatments for neurological conditions and strengthens its financial position, potentially enhancing its market standing and providing benefits for stakeholders.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company that focuses on the development and commercialization of the drug Exenatide, specifically repurposed to treat neurological conditions associated with raised intracranial pressure. The company has trademarked this repurposed drug as Presendin™.
YTD Price Performance: 2.86%
Average Trading Volume: 16,245
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$5.26M
Find detailed analytics on IXC stock on TipRanks’ Stock Analysis page.